CClinicalTrials.gg
RecruitingNCT07488598Updated Apr 23, 2026

Efficacy of Behavioral Therapy for Chronic Refractory Cough

An interventional study of Behavioral Therapy in Chronic Cough, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Chronic cough is defined as cough persisting for more than eight weeks. It is a common clinical problem that significantly impairs patients' physical, psychological, and social quality of life. Chronic cough remains a diagnostic and therapeutic challenge despite systematic evaluation and treatment of common etiologies such as asthma, gastroesophageal reflux disease

Read the detailed description

Chronic cough is defined as cough persisting for more than eight weeks. It is a common clinical problem that significantly impairs patients' physical, psychological, and social quality of life. Chronic cough remains a diagnostic and therapeutic challenge despite systematic evaluation and treatment of common etiologies such as asthma, gastroesophageal reflux disease .

A substantial proportion of patients continue to experience persistent symptoms and are increasingly classified under the umbrella of cough hypersensitivity syndrome, characterized by an exaggerated cough response to low-level mechanical, chemical, or thermal stimuli .

Laryngeal hyperresponsiveness represents a central pathophysiological feature of upper air way cough syndrome and is associated with heightened sensory and motor responses of the larynx, leading to symptoms such as throat irritation, dysphonia, frequent throat clearing, and cough triggered by talking, laughing, cold air, or exposure to strong odors.

Pharmacological therapies often provide limited or inconsistent benefit in those patients,prompting growing interest in non-pharmacological approaches, particularly behavioral cough suppression therapy delivered by speech-language pathologists.

Behavioral therapy is a multimodal intervention incorporating patient education, cough suppression techniques, breathing retraining, vocal hygiene counseling, and strategies aimed at reducing laryngeal irritation and maladaptive cough behaviors and improve voluntary control of the urge to cough.

Randomized controlled trials and observational studies have demonstrated that behavioral therapy can significantly reduce cough frequency, cough reflex sensitivity, and cough-related quality-of-life impairment, with particular benefit observed in patients with prominent laryngeal symptoms and heightened urge-to-cough.

A recent meta-analysis of 12 randomized and self-controlled trials provides robust evidence for Behavioral Cough Suppression Therapy (BCST), showing it significantly improves Leicester Cough Questionnaire scores and reduces objective cough frequency in patients with refractory or unexplained chronic cough.

Furthermore, a specific protocol known as Physiotherapy and Speech and Language Therapy Intervention (PSALTI) has demonstrated a 41% reduction in cough frequency in clinical trials.

Despite the Advantages of speech pathology intervention, there is limited guidance in the literature on when patients should be referred for treatment. Also, heterogeneity in patient selection, diagnostic criteria, and outcome measures highlights the Need for further evaluation of the Efficacy of behavioral therapy in well-defined population with laryngeal hyperresponsivness.

02

Conditions studied

  • Chronic Cough

Browse trials for

03

In context

Chronic Cough

140 studies on the registry are indexed under Chronic Cough; 37 are open to participants now.

This study's planned enrollment of 30 is below the median of 56 across 105 interventional studies indexed under Chronic Cough.

Browse Chronic Cough studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Eligible participants are adults aged ≥18 years i.e. normal chest radiograph.
  • participants with chronic cough persisting for more than eight weeks that is refractory to standard medical treatment for common causes of chronic cough, including asthma, gastroesophageal reflux disease .
  • Participants are required to exhibit clinical features suggestive of laryngeal hyperresponsiveness, such as cough triggered by phonation, laughter, cold air, or irritant exposure, with associated laryngeal symptoms including throat irritation, dysphonia, or frequent throat clearing.

Exclusion criteria

Exclusion Criteria:

  • Patients are excluded if they are current smokers or had ceased smoking within six months
  • patients have evidence of active pulmonary or cardiac disease, recent respiratory tract infection, recent angiotensin-converting enzyme inhibitor use.
  • significant structural laryngeal pathology, neurological disorders affecting cough reflex control, or inability to comply with study procedures.
  • Head \&neck pathology e.g sinusitis, glottal insufficiency or primary muscle tension dysphonia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Behavioral Therapy for chronic cough

    About 30 patients suffering from chronic cough persisting for more than eight weeks that is refractory to standard medical treatment for common causes of chronic cough, including asthma, gastroesophageal reflux disease

    Behavioral: Behavioral Therapy

Interventions

  • BehavioralBehavioral Therapy

    to evaluate the efficacy of behavioral therapy for chronic cough in patients with laryngeal hyperresponsiveness in order to assess its role as a non-pharmacological management strategy. This will provide an efficient plan of therapy for such challenging condition.

    Also known as: Laryngeal hyperresponsiveness

06

What researchers measure

Primary outcomes

  1. Treatment of Chronic Cough

    The patient's subjective response to treatment, categorized as: resolved, improved, no change, or worse. it will be assisted by Cough-Specific Quality of Life: Leicester Cough Questionnaire (LCQ): The primary measure of cough-specific health-related quality of life (QoL). and also assesses physical, psychological, and social domains

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Assuit University hospitals
    Asyut, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07488598
Lead sponsor
Assiut University
Responsible party
Mohamed Shaaban Mohamed (Resident at of Phoniatric, ENT Department,Faculty of Medicine, Assiut University) — Principal investigator
First posted
Mar 23, 2026
Start date
Mar 10, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
May 10, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Mohamed Shaaban Mohamed Mahfouz, Resident
Contact
mhamedshaaban6@gmail.com
+201094817965
Eman Sayed Hassan, Professor
study chair · Head of Phoniatric unit,ENT Department,Faculty of Medicine, Assiut University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion